So, you know, RNA sequencing is a mature technology. It’s readily accessible. For our trial, we use Tempus, which is a commercially available genomics company, which a lot of practices use across the country. And so it’s not an issue of technology development. If anything, it would be nice to be able to validate this data with a larger cohort. And so we’re talking to people and investigating multiple creative ways of getting that done...
So, you know, RNA sequencing is a mature technology. It’s readily accessible. For our trial, we use Tempus, which is a commercially available genomics company, which a lot of practices use across the country. And so it’s not an issue of technology development. If anything, it would be nice to be able to validate this data with a larger cohort. And so we’re talking to people and investigating multiple creative ways of getting that done. But the technology is there. The infrastructure is there. So I think we’re nearer to this than we are to almost, you know, to a lot of different biomarkers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
